senate Bill S2186A

Signed By Governor
2013-2014 Legislative Session

Provides that persons with clotting protein deficiencies who are otherwise eligible for certain health insurance programs shall have access to reimbursement for certain treatments

download bill text pdf

Sponsored By

Archive: Last Bill Status Via A962 -


  • Introduced
  • In Committee
  • On Floor Calendar
    • Passed Senate
    • Passed Assembly
  • Delivered to Governor
  • Signed by Governor

do you support this legislation?

You must fill out the form below in order to support or oppose this bill. X

You must login or fill out the fields below for the senator to have an accurate account of the support or opposition to this bill.

Create an account. An account allows you to officially support or oppose key legislation, sign petitions with a single click, and follow issues, committees, and bills that matter to you. When you create an account, you agree to this platform's terms of participation.
Use this box to enter a message to your senator.

Actions

view actions (13)
Assembly Actions - Lowercase
Senate Actions - UPPERCASE
Oct 23, 2013 signed chap.428
Oct 11, 2013 delivered to governor
Jun 18, 2013 returned to assembly
passed senate
3rd reading cal.1425
substituted for s2186a
Jun 18, 2013 substituted by a962a
ordered to third reading cal.1425
committee discharged and committed to rules
Jun 10, 2013 reported and committed to finance
May 22, 2013 print number 2186a
amend (t) and recommit to health
Jan 14, 2013 referred to health

Co-Sponsors

view additional co-sponsors

S2186 - Details

See Assembly Version of this Bill:
A962A
Law Section:
Public Health Law
Laws Affected:
Amd §2510, Pub Health L
Versions Introduced in 2011-2012 Legislative Session:
S3865, S3865A, A6039A

S2186 - Summary

Provides that persons with hemophilia and other clotting protein deficiencies who are otherwise eligible for the Child Health Plus program shall have access to reimbursement for outpatient blood clotting factor concentrates and other necessary treatments and services.

S2186 - Sponsor Memo

S2186 - Bill Text download pdf

                    S T A T E   O F   N E W   Y O R K
________________________________________________________________________

                                  2186

                       2013-2014 Regular Sessions

                            I N  S E N A T E

                            January 14, 2013
                               ___________

Introduced  by  Sen.  ROBACH -- read twice and ordered printed, and when
  printed to be committed to the Committee on Health

AN ACT to amend the public health law and the social  services  law,  in
  relation  to providing that persons with hemophilia and other clotting
  protein deficiencies who are otherwise eligible for the  Child  Health
  Plus or Family Health Plus programs shall have access to reimbursement
  for  outpatient blood clotting factor concentrates and other necessary
  treatments and services

  THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND  ASSEM-
BLY, DO ENACT AS FOLLOWS:

  Section  1.    Legislative  findings.  Hemophilia is a rare hereditary
bleeding disorder resulting from a deficiency in blood proteins known as
clotting factors.  Without an adequate supply of clotting factors, indi-
viduals can experience prolonged bleeding following routine medical  and
dental  procedures,  trauma,  and  a range of physical activities. Addi-
tionally,  individuals  with  hemophilia  often  experience  spontaneous
internal  bleeding that can cause severe joint damage, chronic pain, and
even death.
  Prior to the 1970s, individuals with hemophilia  seldom  lived  beyond
the age of 30 years. Early treatment consisted of whole blood and plasma
transfusions at hospitals. These treatments were difficult, time consum-
ing  and  only  minimally effective. The advent of commercially prepared
blood clotting factors in the  1980s  represented  a  major  advance  in
treatment,  both in terms of efficacy and convenience. Most importantly,
these advances allowed for home infusion.
  In addition to hemophilia, there are several other disorders resulting
from blood protein deficiencies. These include  Von  Willebrand  Disease
(VWD),  the  most  common bleeding disorder, affecting approximately two
million Americans. Individuals with the severest form  of  VWD  rely  on
clotting  factor  treatments  similar  to those used by individuals with
hemophilia.

 EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
                      [ ] is old law to be omitted.
                                                           LBD02168-01-3

Co-Sponsors

view additional co-sponsors

S2186A (ACTIVE) - Details

See Assembly Version of this Bill:
A962A
Law Section:
Public Health Law
Laws Affected:
Amd §2510, Pub Health L
Versions Introduced in 2011-2012 Legislative Session:
S3865, S3865A, A6039A

S2186A (ACTIVE) - Summary

Provides that persons with hemophilia and other clotting protein deficiencies who are otherwise eligible for the Child Health Plus program shall have access to reimbursement for outpatient blood clotting factor concentrates and other necessary treatments and services.

S2186A (ACTIVE) - Sponsor Memo

S2186A (ACTIVE) - Bill Text download pdf

                    S T A T E   O F   N E W   Y O R K
________________________________________________________________________

                                 2186--A

                       2013-2014 Regular Sessions

                            I N  S E N A T E

                            January 14, 2013
                               ___________

Introduced  by Sens. ROBACH, ADAMS, BRESLIN, GRISANTI, MARCHIONE, NOZZO-
  LIO, PARKER, VALESKY -- read  twice  and  ordered  printed,  and  when
  printed  to  be  committed  to  the  Committee  on Health -- committee
  discharged, bill amended, ordered reprinted as amended and recommitted
  to said committee

AN ACT to amend the public health law, in  relation  to  providing  that
  persons  with  hemophilia  and other clotting protein deficiencies who
  are otherwise eligible for the Child Health Plus  program  shall  have
  access  to  reimbursement for outpatient blood clotting factor concen-
  trates and other necessary treatments and services

  THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND  ASSEM-
BLY, DO ENACT AS FOLLOWS:

  Section  1.    Legislative  findings.  Hemophilia is a rare hereditary
bleeding disorder resulting from a deficiency in blood proteins known as
clotting factors.  Without an adequate supply of clotting factors, indi-
viduals can experience prolonged bleeding following routine medical  and
dental  procedures,  trauma,  and  a range of physical activities. Addi-
tionally,  individuals  with  hemophilia  often  experience  spontaneous
internal  bleeding that can cause severe joint damage, chronic pain, and
even death.
  Prior to the 1970s, individuals with hemophilia  seldom  lived  beyond
the age of 30 years. Early treatment consisted of whole blood and plasma
transfusions at hospitals. These treatments were difficult, time consum-
ing  and  only  minimally effective. The advent of commercially prepared
blood clotting factors in the  1980s  represented  a  major  advance  in
treatment,  both in terms of efficacy and convenience. Most importantly,
these advances allowed for home infusion.
  In addition to hemophilia, there are several other disorders resulting
from blood protein deficiencies. These include  Von  Willebrand  Disease
(VWD),  the  most  common bleeding disorder, affecting approximately two
million Americans. Individuals with the severest form  of  VWD  rely  on

 EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
                      [ ] is old law to be omitted.
                                                           LBD02168-05-3

Comments

Open Legislation comments facilitate discussion of New York State legislation. All comments are subject to moderation. Comments deemed off-topic, commercial, campaign-related, self-promotional; or that contain profanity or hate speech; or that link to sites outside of the nysenate.gov domain are not permitted, and will not be published. Comment moderation is generally performed Monday through Friday.

By contributing or voting you agree to the Terms of Participation and verify you are over 13.